Epidemiological studies have reported inconsistent findings for the association between B vitamins and breast cancer (BC) risk. We investigated the relationship between biomarkers of folate and vitamin B12 and the risk of BC in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Plasma concentrations of folate and vitamin B12 were determined in 2,491 BC cases individually matched to 2,521 controls among women who provided baseline blood samples. Multivariable logistic regression models were used to estimate odds ratios by quartiles of either plasma B vitamin. Subgroup analyses by menopausal status, hormone receptor status of breast tumors (estrogen receptor [ER], progesterone receptor [PR] and human epidermal growth factor receptor 2 [HER2]), alcohol intake and MTHFR polymorphisms (677C > T and 1298A > C) were also performed. Plasma levels of folate and vitamin B12 were not significantly associated with the overall risk of BC or by hormone receptor status. A marginally positive association was found between vitamin B12 status and BC risk in women consuming above the median level of alcohol (ORQ4-Q1 = 1.26; 95% CI 1.00–1.58; Ptrend = 0.05). Vitamin B12 status was also positively associated with BC risk in women with plasma folate levels below the median value (ORQ4-Q1 = 1.29; 95% CI 1.02–1.62; Ptrend = 0.03). Overall, folate and vitamin B12 status was not clearly associated with BC risk in this prospective cohort study. However, potential interactions between vitamin B12 and alcohol or folate on the risk of BC deserve further investigation.

Biomarkers of folate and vitamin B12 and breast cancer risk: report from the EPIC cohort

Ricceri F.;
2017-01-01

Abstract

Epidemiological studies have reported inconsistent findings for the association between B vitamins and breast cancer (BC) risk. We investigated the relationship between biomarkers of folate and vitamin B12 and the risk of BC in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Plasma concentrations of folate and vitamin B12 were determined in 2,491 BC cases individually matched to 2,521 controls among women who provided baseline blood samples. Multivariable logistic regression models were used to estimate odds ratios by quartiles of either plasma B vitamin. Subgroup analyses by menopausal status, hormone receptor status of breast tumors (estrogen receptor [ER], progesterone receptor [PR] and human epidermal growth factor receptor 2 [HER2]), alcohol intake and MTHFR polymorphisms (677C > T and 1298A > C) were also performed. Plasma levels of folate and vitamin B12 were not significantly associated with the overall risk of BC or by hormone receptor status. A marginally positive association was found between vitamin B12 status and BC risk in women consuming above the median level of alcohol (ORQ4-Q1 = 1.26; 95% CI 1.00–1.58; Ptrend = 0.05). Vitamin B12 status was also positively associated with BC risk in women with plasma folate levels below the median value (ORQ4-Q1 = 1.29; 95% CI 1.02–1.62; Ptrend = 0.03). Overall, folate and vitamin B12 status was not clearly associated with BC risk in this prospective cohort study. However, potential interactions between vitamin B12 and alcohol or folate on the risk of BC deserve further investigation.
2017
140
6
1246
1259
alcohol; breast cancer; folate; hormone receptor status; MTHFR polymorphism; plasma biomarkers; vitamin B12; Adult; Aged; Alcohol Drinking; Biomarkers; Breast Neoplasms; Case-Control Studies; Diet; Estrogens; Europe; Female; Folic Acid; Folic Acid Deficiency; Follow-Up Studies; Genes, erbB-2; Humans; Life Style; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasms, Hormone-Dependent; Polymorphism, Single Nucleotide; Progesterone; Risk Factors; Vitamin B 12; Vitamin B 12 Deficiency
Matejcic M.; de Batlle J.; Ricci C.; Biessy C.; Perrier F.; Huybrechts I.; Weiderpass E.; Boutron-Ruault M.C.; Cadeau C.; His M.; Cox D.G.; Boeing H.; Fortner R.T.; Kaaks R.; Lagiou P.; Trichopoulou A.; Benetou V.; Tumino R.; Panico S.; Sieri S.; Palli D.; Ricceri F.; Bueno-de-Mesquita H.B.; Skeie G.; Amiano P.; Sanchez M.J.; Chirlaque M.D.; Barricarte A.; Quiros J.R.; Buckland G.; van Gils C.H.; Peeters P.H.; Key T.J.; Riboli E.; Gylling B.; Zeleniuch-Jacquotte A.; Gunter M.J.; Romieu I.; Chajes V.
File in questo prodotto:
File Dimensione Formato  
Matejcicetal2017_IJC.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 256.13 kB
Formato Adobe PDF
256.13 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Biomarkers of folate and vitamin B12 and breast cancer risk.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 272.49 kB
Formato Adobe PDF
272.49 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1766555
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 34
social impact